Table 3 ORRs of different subgroups assessed by IRC per RECIST v1.1
Subgroup | Response/Patients | ORR, % (95%CI) | |
|---|---|---|---|
Overall | 24/119 | 20.17 (13.37–28.51) | |
Age |  < 65 | 15/92 | 16.30 (9.42–25.46) |
 ≥ 65 | 9/27 | 33.33 (16.52–53.96) | |
Gender | Male | 9/51 | 17.65 (8.40–30.87) |
Female | 15/68 | 22.06 (12.90–33.76) | |
ECOG PS | 0 | 11/51 | 21.57 (11.29–35.32) |
1 | 13/68 | 19.12 (10.59–30.47) | |
Melanoma subtypes | Non-acral cutaneous | 8/22 | 36.36 (17.20–59.34) |
Acral | 10/62 | 16.13 (8.02–27.67) | |
Mucosal | 2/23 | 8.70 (1.07–28.04) | |
Unknown | 4/12 | 33.33 (9.92–65.11) | |
Distant metastasis | No | 3/27 | 11.11 (2.35–29.16) |
Yes | 17/76 | 22.37 (13.60–33.38) | |
ADA | Positive | 0/4 | 0 |
Negative | 24/112 | 21.43 (14.24–30.19) | |
Liver metastasis | Yes | 1/15 | 6.67 (0,17–31.95) |
No | 23/104 | 22.12 (14.57–31.31) | |
BRAF mutation | Yes | 5/13 | 38.46 (13.86–68.42) |
No | 8/47 | 17.02 (7.65–30.81) | |
NRAS mutation | Yes | 1/9 | 11.11 (0.28–48.25) |
No | 0/1 | 0 | |
Baseline LDH | Normal | 18/72 | 25.00 (14.75–35.25) |
Higher than upper limit of normal (ULN) | 6/47 | 12.77 (2.86–22.67) | |